Centessa Pharmaceuticals Plc ADR (NQ: CNTA )
4.610 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Jun 9, 2023 Add to My Watchlist
Press Releases about Centessa Pharmaceuticals Plc ADR
Centessa Pharmaceuticals Plc (NASDAQ:CNTA) Long Term Shareholder Notice: Investigation of Potential Wrongdoing
February 14, 2023
San Diego, CA -- (SBWIRE) -- 02/14/2023 -- An investigation was announced for investors in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) concerning potential breaches of fiduciary duties by...
Centessa Pharmaceuticals Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of LB101, First LockBody® Candidate, for Solid Tumors
January 26, 2023
LB101 is a conditionally tetravalent PD-L1xCD47 LockBody bispecific monoclonal antibody being developed for solid tumors
CENTESSA PHARMACEUTICALS 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess Of $100,000 of Deadline in Class Action Lawsuit Against Centessa Pharmaceuticals plc - CNTA
November 25, 2022
Centessa Pharmaceuticals to Present Additional 18-Months of Continued Treatment Data with SerpinPC from Open-Label Extension of Phase 2a Study at 64th ASH Annual Meeting
November 03, 2022
New efficacy and safety data from 18-months of continued treatment with subcutaneous doses of SerpinPC in subjects with hemophilia accepted for oral presentation
NASDAQ:CNTA Shareholder Notice: Lawsuit Alleges Securities Laws Violations by Centessa Pharmaceuticals Plc
October 12, 2022
San Diego, CA -- (SBWIRE) -- 10/12/2022 -- An investor, who purchased shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA), filed a lawsuit against Centessa Pharmaceuticals plc over alleged Federal...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following